News and updates

Oncgnostics GmbH is greatly honoured to have been selected by EURONEXT for the TechShare programme. We will be participating in top-class workshops and coaching sessions for half a year. High-quality Coaching for Start-ups As one of eleven German start-ups in the medical and biotech sectors, we will have the opportunity to broaden our horizons over […]

Dr. Alfred Hansel in Spanien

On 12 June, the conference ‘XIII Jornada de Formación en Patología del Tracto Genital inferior y Colposcopia‘ was held in Madrid. Oncgnostics’ managing director Dr Alfred Hansel was one of the speakers at the training event for gynaecologists. Experts Exchange Knowledge At the conference, experts updated their knowledge on HPV-related cancers in women’s genital tract. […]

Investor Days

On 18 June oncgnostics managing director, Dr Alfred Hansel, visited Investor Days Thüringen in Erfurt, and was pleased to receive the ‘bm|t sustainable business award’. Thuringia’s Sector Network Meeting As a large sector network meeting, Investor Days bring together the different parties involved: Young companies, investors, decision makers and representatives from economy, science and politics. […]

ICHNO 2019

The International Congress on Innovative Approaches in Head and Neck Oncology (ICHNO) took place, for the seventh time, in Barcelona from 14 to 16 March. Anna-Bawany Hums participated in the interdisciplinary exchange of experts on behalf of oncgnostics GmbH. Specialists from all over the World Among the approximately 600 international participants, there were clinicians from […]

Indien oncgnostics GmbH

From the 9 to the 16 In February, our managing director Dr Martina Schmitz travelled to India as a participant of the delegation trip ‘Thuringia goes India’. There she got an impression of the Indian market and made first contacts. The trip took place under the direction of Wolfgang Tiefensee, Thuringia’s Minister for Economic Affairs, […]

Jena, 20. February, 2019 – The test for early detection of cervical cancer GynTect® may now also be performed on the cobas Z480 analyzer, a widely used quantitative PCR (QPCR) system from Roche Diagnostics. This is now possible through an extension of the GynTect® CE IVD mark (CE mark for in vitro diagnostics). The biotech […]

Oncgnostics will discuss new clinical data with gynaecological key opinion leaders at EUROGIN 2018 SAN FRANCISCO, CA, USA, November 29, 2018 — Oncgnostics GmbH presents new clinical data on GynTect® Precision Diagnostics for triage of unclear cervical cancer screening tests. Oncgnostics GmbH, a Jena/Germany based company, has developed GynTect® for precision detection of cervical cancer. […]

Jena, October 17, 2018 – The Thuringian molecular diagnostics company oncgnostics, which quickly and successfully closed a 750,000 Euros crowd-investing round on Seedmatch early in 2018, now announces the closing of another similarly sized round. oncgnostics has developed the cervical cancer diagnostics test GynTect®, and a private investor circle now invests together with the  current […]

Logo Biotech Alliances International

2018-10-02 San Francisco/Jena, Germany: Biotech Alliances International Inc., a Silicon Valley-based healthcare-focused investment bank, announced today that it will serve as the lead investment banker to Oncgnostics globalisation and partnering strategy. Early detection of cervical cancer is critical for patient’s health and survival.  Current diagnostic methods are inefficient and fail to detect 50% of the […]

Although cervical cancer and uterine (body) cancer develop only a few centimetres apart, there are big differences in the cause of the disease. Therefore, the fields of research and treatment are also fundamentally different. This article will explain the differences, for a better understanding. First, anatomy, in order to be able to better classify where […]